Cargando…

A Randomised, Double-Blind, Placebo-Controlled Crossover Trial of Resveratrol Supplementation for Prophylaxis of Hormonal Migraine

Resveratrol, a vasoactive phytoestrogen, has beneficial effects on cerebrovascular function. Previous research has shown that hormonal migraineurs have poorer cerebrovascular function than non-migraineur women. We aimed to investigate if resveratrol supplementation for three months could reduce the...

Descripción completa

Detalles Bibliográficos
Autores principales: Dzator, Jemima S. A., Howe, Peter R. C., Coupland, Kirsten G., Wong, Rachel H. X.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9100551/
https://www.ncbi.nlm.nih.gov/pubmed/35565731
http://dx.doi.org/10.3390/nu14091763
_version_ 1784706873074647040
author Dzator, Jemima S. A.
Howe, Peter R. C.
Coupland, Kirsten G.
Wong, Rachel H. X.
author_facet Dzator, Jemima S. A.
Howe, Peter R. C.
Coupland, Kirsten G.
Wong, Rachel H. X.
author_sort Dzator, Jemima S. A.
collection PubMed
description Resveratrol, a vasoactive phytoestrogen, has beneficial effects on cerebrovascular function. Previous research has shown that hormonal migraineurs have poorer cerebrovascular function than non-migraineur women. We aimed to investigate if resveratrol supplementation for three months could reduce the hormonal migraine burden index (HMBI: the number of days with menstrual migraine per month), reduce migraine-related disability and improve migraine-related quality of life. A randomised, double-blind, placebo-controlled, crossover, intervention trial was conducted in 62 hormonal migraineurs (mean age: 37.5 ± 0.8 years). Participants consumed 75 mg of resveratrol or matching placebo capsules twice daily for three months before crossing over to the other treatment arm. Participants completed a daily diary and the Headache Impact Test-6™, Migraine Disability Assessment and Migraine-Specific Quality of Life questionnaires at months 0, 3 and 6. The HMBI was the primary outcome and was calculated using data extracted from the participant’s diary. No differences in the HMBI (p = 0.895), the Headache Impact Test-6™, the Migraine Disability Assessment and Migraine-Specific Quality of Life were found between the resveratrol and placebo treatments. Resveratrol supplementation for three months did not affect the HMBI, the migraine-related disability or quality of life measures in our cohort of hormonal migraineurs.
format Online
Article
Text
id pubmed-9100551
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91005512022-05-14 A Randomised, Double-Blind, Placebo-Controlled Crossover Trial of Resveratrol Supplementation for Prophylaxis of Hormonal Migraine Dzator, Jemima S. A. Howe, Peter R. C. Coupland, Kirsten G. Wong, Rachel H. X. Nutrients Article Resveratrol, a vasoactive phytoestrogen, has beneficial effects on cerebrovascular function. Previous research has shown that hormonal migraineurs have poorer cerebrovascular function than non-migraineur women. We aimed to investigate if resveratrol supplementation for three months could reduce the hormonal migraine burden index (HMBI: the number of days with menstrual migraine per month), reduce migraine-related disability and improve migraine-related quality of life. A randomised, double-blind, placebo-controlled, crossover, intervention trial was conducted in 62 hormonal migraineurs (mean age: 37.5 ± 0.8 years). Participants consumed 75 mg of resveratrol or matching placebo capsules twice daily for three months before crossing over to the other treatment arm. Participants completed a daily diary and the Headache Impact Test-6™, Migraine Disability Assessment and Migraine-Specific Quality of Life questionnaires at months 0, 3 and 6. The HMBI was the primary outcome and was calculated using data extracted from the participant’s diary. No differences in the HMBI (p = 0.895), the Headache Impact Test-6™, the Migraine Disability Assessment and Migraine-Specific Quality of Life were found between the resveratrol and placebo treatments. Resveratrol supplementation for three months did not affect the HMBI, the migraine-related disability or quality of life measures in our cohort of hormonal migraineurs. MDPI 2022-04-22 /pmc/articles/PMC9100551/ /pubmed/35565731 http://dx.doi.org/10.3390/nu14091763 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Dzator, Jemima S. A.
Howe, Peter R. C.
Coupland, Kirsten G.
Wong, Rachel H. X.
A Randomised, Double-Blind, Placebo-Controlled Crossover Trial of Resveratrol Supplementation for Prophylaxis of Hormonal Migraine
title A Randomised, Double-Blind, Placebo-Controlled Crossover Trial of Resveratrol Supplementation for Prophylaxis of Hormonal Migraine
title_full A Randomised, Double-Blind, Placebo-Controlled Crossover Trial of Resveratrol Supplementation for Prophylaxis of Hormonal Migraine
title_fullStr A Randomised, Double-Blind, Placebo-Controlled Crossover Trial of Resveratrol Supplementation for Prophylaxis of Hormonal Migraine
title_full_unstemmed A Randomised, Double-Blind, Placebo-Controlled Crossover Trial of Resveratrol Supplementation for Prophylaxis of Hormonal Migraine
title_short A Randomised, Double-Blind, Placebo-Controlled Crossover Trial of Resveratrol Supplementation for Prophylaxis of Hormonal Migraine
title_sort randomised, double-blind, placebo-controlled crossover trial of resveratrol supplementation for prophylaxis of hormonal migraine
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9100551/
https://www.ncbi.nlm.nih.gov/pubmed/35565731
http://dx.doi.org/10.3390/nu14091763
work_keys_str_mv AT dzatorjemimasa arandomiseddoubleblindplacebocontrolledcrossovertrialofresveratrolsupplementationforprophylaxisofhormonalmigraine
AT howepeterrc arandomiseddoubleblindplacebocontrolledcrossovertrialofresveratrolsupplementationforprophylaxisofhormonalmigraine
AT couplandkirsteng arandomiseddoubleblindplacebocontrolledcrossovertrialofresveratrolsupplementationforprophylaxisofhormonalmigraine
AT wongrachelhx arandomiseddoubleblindplacebocontrolledcrossovertrialofresveratrolsupplementationforprophylaxisofhormonalmigraine
AT dzatorjemimasa randomiseddoubleblindplacebocontrolledcrossovertrialofresveratrolsupplementationforprophylaxisofhormonalmigraine
AT howepeterrc randomiseddoubleblindplacebocontrolledcrossovertrialofresveratrolsupplementationforprophylaxisofhormonalmigraine
AT couplandkirsteng randomiseddoubleblindplacebocontrolledcrossovertrialofresveratrolsupplementationforprophylaxisofhormonalmigraine
AT wongrachelhx randomiseddoubleblindplacebocontrolledcrossovertrialofresveratrolsupplementationforprophylaxisofhormonalmigraine